Back to mobile site

Heat Biologics (HTBX) Gains on HS-110 Phase 2 Trial Abstract

February 26, 2019 7:11 AM EST Send to a Friend
Heat Biologics (NASDAQ: HTBX) is gaining 23% in pre-open trade after the company disclosed that in connection with the planned ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login